The Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma
Overview
- Phase
- N/A
- Intervention
- Sintilimab (PD-1 inhibitor)
- Conditions
- Resectable Esophageal Squamous Cell Carcinoma
- Sponsor
- Tang-Du Hospital
- Enrollment
- 90
- Locations
- 1
- Primary Endpoint
- complete pathologic response (pCR)
- Status
- Enrolling by Invitation
- Last Updated
- last year
Overview
Brief Summary
This study is an open-label, prospective, cohort clinical study to evaluate the safety and efficacy of different cycles of sintilimab in combination with platinum-containing chemotherapy as preoperative neoadjuvant therapy in patients with resectable esophageal cancer. In the study, all subjects who meet the enrollment criteria will be randomized 1:1:1 to receive sintilimab combined with platinum-containing chemotherapy Q3W for 3 cycles (Group A), sintilimab combined with platinum-containing chemotherapy Q3W for 2 cycles + sintilimab for 1 cycle (Group B), sintilimab combined with platinum-containing chemotherapy for 1 cycle + sintilimab Q3W for 2 cycles (Group B) as neoadjuvant therapy, and receive radical surgery within 4-6 weeks after the completion of the last neoadjuvant therapy. Whether the subjects need adjuvant therapy and adjuvant treatment regimen after surgery are determined by the investigator, and all subjects need to complete the follow-up plan formulated by the study after surgery.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Preoperative gastroscopy showed that the main body of the tumor was located.
- •Patients with potentially resectable esophageal cancer evaluated by preoperative imaging (chest contrast-enhanced CT, head CT or MRI, abdominal B-ultrasound, PET/CT), and the potentially resectable patients refer to the 2018 edition of the Diagnosis and Treatment Standards for Esophageal Cancer formulated by the National Health and Wellness Commission, defined as patients with esophageal cancer stage T2-3, N0/N+, M0 or T4a, N0-1, M0 (8th edition AJCC stage in 2017).
- •Signed informed consent and met all the inclusion criteria of this study. 4）aged 18\~75 years old 5）ECOG PS score of 0-1;
Exclusion Criteria
- •prior treatment with immune checkpoint inhibitors, including but not limited to anti-CTLA-4, anti-PD-1 and anti-PD-L1 therapeutic antibodies, and OX-40;
- •.previous systemic therapy;
- •current participation in an interventional clinical trial or receipt of another investigational drug or medical intervention within 4 weeks;
- •presence of active hemoptysis, active diverticulitis, abdominal abscess, gastrointestinal obstruction (or other factors affecting the absorption of oral medications such as inability to swallow, nausea and vomiting, abnormal physiologic function, malabsorption syndrome, etc.) that require clinical intervention
- •the presence of any signs or history of bleeding constitution; the presence of unhealed wounds, ulcers, or fractures in patients who have experienced any bleeding or hemorrhagic event ≥ CTCAE Grade 3 within 4 weeks prior to enrollment; -
Arms & Interventions
Group A
sintilimab combined with platinum-containing chemotherapy Q3W for 3 cycles
Intervention: Sintilimab (PD-1 inhibitor)
Group B
sintilimab combined with platinum-containing chemotherapy Q3W for 2 cycles + sintilimab for 1 cycle
Intervention: Sintilimab (PD-1 inhibitor)
Group C
sintilimab combined with platinum-containing chemotherapy for 1 cycle + sintilimab Q3W for 2 cycles
Intervention: Sintilimab (PD-1 inhibitor)
Outcomes
Primary Outcomes
complete pathologic response (pCR)
Time Frame: 3 mouths
no residual tumor cells in the surgically resected tumor specimen and all sampled regional lymph nodes after neoadjuvant treatment.